CAR T cells, engineered immune cells, have become a leading therapy for various types of blood cancer. Despite initial skepticism from the scientific community during their development in the 1990s, CAR T cells are now seen as powerful treatment options and may extend their use to brain cancer and other conditions. However, the laborious process of creating CAR T cells leads to inefficiencies, delays in treatment, and high costs, limiting accessibility for many patients.
"This whole process, it's just inefficient," says Saar Gill, a haematologist and oncologist also at the Perelman School of Medicine.
When they presented their research at meetings, "we were in the last session on the last day, in a room no one could find".
Studies suggest that they might hold promise for brain cancer and other solid tumours, as well as autoimmune and other diseases.
The value of the CAR-T-therapy market... is expected to hit US$11 billion this year and grow to nearly $190 billion by 2034.
Collection
[
|
...
]